Is Still's Disease an Autoinflammatory Syndrome?

Area of Science:

• Pediatric Rheumatology
• Immunology
• Autoinflammatory Diseases

Background:

• Systemic juvenile idiopathic arthritis (sJIA), also known as Still's disease, is a distinct subset of juvenile idiopathic arthritis (JIA).
• sJIA presents with significant systemic features and inflammation, differentiating it from other JIA subtypes.
• Unlike other JIA forms, sJIA lacks association with HLA genes or autoantibodies, suggesting a unique pathogenesis.

Purpose of the Study:

• To re-evaluate the classification and pathogenesis of sJIA based on distinct clinical and laboratory findings.
• To highlight sJIA's classification as an autoinflammatory disease rooted in innate immune system dysfunction.
• To discuss the impact of new pathogenetic insights on therapeutic strategies for sJIA.

Main Methods:

• Clinical and laboratory feature analysis of sJIA patients.
• Review of current literature on sJIA pathogenesis, focusing on immune system activation.
• Evaluation of treatment outcomes with targeted therapies.

Main Results:

• sJIA is characterized by uncontrolled phagocyte activation and hypersecretion of IL-1 and IL-6.
• Evidence supports sJIA as an autoinflammatory disease due to innate immune system abnormalities.
• Targeted therapies, including anti-IL-1 and anti-IL-6 agents, demonstrate improved efficacy and safety.

Conclusions:

• sJIA represents a distinct autoinflammatory condition separate from other JIA forms.
• Understanding sJIA's pathogenesis is crucial for effective treatment.
• Targeted therapies targeting IL-1 and IL-6 pathways offer a more effective and safer treatment approach for sJIA.